Viking Therapeutics Reported Weight Loss Drug Success
Trial participants achieved significant weight loss and maintained results through flexible dosing schedules.
Updated on Sept. 23, 2026 in Weight Loss
Live Poll
Do you believe the recent developments in weight loss drugs will lead to better health outcomes?
Viking Therapeutics announced that its investigational drug VK2735 led to 21.7 percent weight loss at 33 weeks in trial participants. These results arrive as multiple pharmaceutical companies release data on new obesity treatment candidates.
Why it matters
The study tested whether transitioning to less frequent injections could help patients maintain weight loss, potentially improving long-term adherence to obesity therapy. Researchers are now evaluating if these outcomes remain stable beyond the 33-week mark.
In a clinical trial, participants receiving weekly injections of VK2735 achieved 21.7 percent weight loss at 33 weeks. Among those who switched to reduced dosing, participants maintained 90 percent of prior weight loss with every-other-week injections and 85 percent with monthly injections.
The players
Viking Therapeutics
A biotechnology company based in San Diego that develops dual-agonist therapies for obesity.
Novo Nordisk
A global pharmaceutical firm known for developing GLP-1 receptor-based treatments for chronic conditions.
Roche
A Switzerland-based healthcare company involved in the research and development of metabolic drugs.
The details
VK2735 functions as a dual agonist that targets both GLP-1 and GIP receptors to regulate metabolic processes. The study design transitioned patients from a 21-week induction period of weekly shots to varied maintenance schedules to determine the efficacy of less frequent dosing. For comparison, participants in the placebo group maintained 61 percent of their prior weight loss.
Timeline
September 21, 2026: Novo Nordisk published CagriSema weight loss data.
September 22, 2026: Viking Therapeutics reported positive trial data for VK2735.
Week 21: Trial participants completed the induction period of the study.
Week 33: Researchers recorded the 21.7 percent weight loss milestone.
Health Landscape
The field of obesity treatment is currently defined by the rapid development of multi-blockbuster drug candidates from several major pharmaceutical firms. This study updates the competitive landscape by showing how new dual-agonist candidates compare to established industry benchmarks.
These results provide insight into how flexible dosing might influence treatment plans in the future. As new weight loss medications move through clinical trials, it is worth discussing the current standard of care and emerging options with your primary physician.
The takeaway
The study suggests that less frequent dosing may effectively support long-term weight management for patients on GLP-1 and GIP dual-agonist therapy. Patients interested in metabolic health should track updates from clinical trials and consult their doctor regarding approved treatment options.
Further reading
For more on the latest research in weight management, visit our Weight Loss section.
Live Poll
Do you believe the recent developments in weight loss drugs will lead to better health outcomes?
